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FURTHER real growth of transplantation will depend 
on the use of animal organs. an elusive goal that 
depends on first understanding how allografts are accepted. 
For nearly 50 years after Medawar l recognized rejection to 
he an immune reaction. an organ allograft (or xenograft) 
was envisioned as a defenseless island under siege in a 
hostile recipient sea. 
THE MYSTERY OF ALLOGRAFT ACCEPTANCE 
When Billingham et ale.J showed that neonatal tolerance 
could be induced by engrafting hematolymphopoietic donor 
cells into immunologically immature mice. the door to 
transplantation was pushed ajar. Simulation of the mouse 
defenseless state with recipient cytoablation4 ultimately 
allowed clinical bone marrow transplantation5- 8 which was 
long viewed as a replacement of the immune system (com-
plete donor leukocyte chimerism). When histoincompatible 
donor bone marrow or spleen cells transplanted into 
mouse9 - 11 and human recipientss.6 .8 rejected the immuno-
logically incompetent recipients. it appeared to be the same 
process in reverse that destroyed organ allografts. 
The resulting unidirectional paradigm of transplantation 
immunology seemingly accommodated the findings follow-
ing bone marrow transplantation, but it did not explain 
organ allograft acceptance. In 1962 to 1963, it was learned 
that organ rejection. which previously had been considered 
inexorable in noncytoablated MHC-incompatible recipi-
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under Immunosuppression :hat IS the practical basIs of organ 
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Fig 2. Time of immunosuppressive treatment (dark shade) and 
time off drug therapy (light) in five non-twin liVing-related kidney 
recipients whose allografts have functioned a third of a century 
or more. LD, living donor. 
ents. could be reversed. I2 Of equal importance, subsequent 
immunosuppression requirements frequently declined. 12 
These two related events were promptly shown to be 
generic. no matter what the baseline drug or what or-
gan. 13-15 Their control is the practical basis of the clinical 
field of transplantation. 
This pattern of convalescence (Fig 1) was delineated 
initially from experience with kidney transplantation under 
treatment with azathioprine and dose-maneuverable pred-
nisone, 12 the first effective double-drug cocktail. At the time 
of this first report. the donor-specific nonreactivity was 
relative and still drug dependent. In some cases. however. 
the tolerance became complete. A third of 3. century later, 
10 (22%) of the first 46 Colorado reCIpients of living-related 
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Fig 3. Time on (black) and off immunosuppression (cross-
hatched) of 12 (28%) of our 42 longest-surviving liver recipients 
(15 to 26 years posttransplant) who have not received treatment 
since December 1995. These drug-free patients remain well in 
August 1996. 
donor kidneys (all treated before 1964) still have function of 
their original allografts. II> 
Five (one half) of these 10 kidney recipients are currently 
drug free, and have been for 3 to 30 years. The cumulative 
time of these patients off drugs equals the time on treat-
ment (Fig 2). Two of the five allografts were from HLA-
identical donors (top and third bars). However, two were 
one-haplotype mismatched (second and bottom bars), and 
one patient received a double-haplotype incompatible kid-
ney from a great aunt (second from bottom). 
Complete tolerance also has been observed repeatedly 
after HLA-mismatched cadaveric liver transplantation. 17 
Among our 42 longest surviving liver recipients-now 15 to 
'27 years posttransplantation-12 (28%) have been drug 
free for as long as 16 years. II> Their cumulative time off 
immunosuppression is almost equal to time treated (Fig 3). 
With more potent baseline drugs. survival of all organ 
grafts rose in three distinct leaps over a 33-year period using 
azathioprine. cyclosporine (CyA). and most recently tacroli-
mus-based immunosuppression. I x However. the sequence 
and timing of immunologic confrontation and resolution 
did not change. It was merely better controlled. 
DISORIENTATION: 1962 TO 1963 
There was. in fact, no explanation whv organ allografts 
would ever survIve. much less routinely. By 1963. donor 
leukocyte chimeTlsm-the means to the end of Medawars 
acquired tolerance and the raISOIl d'etre of bone marrow 
transplantation-was eliminated bv consensus as a factor in 
organ acceptance. It was the beginning of a long trek in the 
wilderness. without a compass. m the wrong direction. 
Passenger Leukocytes: The Putative Enemy 
It was postulated .+0 years Jgo hv George Snell I" (and 
confirmed <.:xperimentallv [20]) that the highly :mtigemc 
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Fig 4. Conventional view of a successfully transplanted allo-
graft In which the nonparenchymal white cells (passenger leu-
kocytes) were assumed to have been destroyed by the host 
immune system. 
passenger leukocytes of bone marrow origin which are a 
component of tissue and organ allografts elicited rejection. 
Consequently. these donor leukocytes were viewed by trans-
planters as "the enemy" that had to be destroyed by the host 
immune system if organ transplantation was to succeed (Fig 
4). This destruction could be envisioned at peripheral as 
well as intragraft sites when it was later learned by Nem-
lander et al 21 Larsen et al,::! Demetris et al. 23 Qian et al,24 
and othersl~-1T that the donor leukocytes (including den-
dritic cells) promptly migrated in the blood to secondary 
lymphoid sites after organ revascularization. 
The Dichotomy of Bone Marrow 
and Organ Transplantation 
The remarkable disparities in treatment and outcome, 
ostensibly involving chimerism for bone marrow but not for 
organ transplantation. sustained the argument for 30 years 
that these two kinds of procedures were successful by 
divergent mechanisms. The differences (Table 1) were 
dependence (bone marrow, left column) vs independence 
on HLA matching (organ. right column). risk vs freedom 
from graft-vs-host disease (GVHD), the frequency with 
which the drug-free state could be achieved. and a semantic 
distinction between bone marrow tolerance on one hand 
and organ graft acceptance on the other. As it turned out, 
all of these dissimilarities were more or less dependent on 
Table 1. The Dichotomy Between Bone Marrow and 
Organ Transplantation 
Bone 
Marrow Organ 
Cntlcal MHC compatibility Not crItIcal 
GVHD Pnnclpal complicatIon ReJectIon 
Common Drug-tree state Rare 
Tolerance Term tor success Acceptance 
Yes ReCIpient cvtoatllatlon' No 
',4.11 arfferences derive from thiS therapeutic steD. 
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·_ ... __ ._ ..•. _--_. __ ._._------ ._._----
FUTURE OF TRANSPLANTATION 
~---1 Immunosuopresslon 
Immune 
Reaction "-, - -. GVH 
-.-, ... ; ," ,"".", ~~ ~K o"I-K:K:~; .- .. -K~ ~: ;.:.-.... ,;, ........ -.... .. 
•••••••. Donor 
Time after TransplantatIOn 
Fig 5. Contemporaneous HVG and GVH reactions in the two-
way paradigm of transplantation Immunology. Following the 
initial interaction. the evolution of nonreactivity of each leukocyte 
population to the other IS seen as a predominantly low-grade 
stimulatory state that may wax and wane, rather than as a 
deletional one. 
a single treatment variable-recipient cytoablation for the 
bone marrow. but not for the organ recipient. 
AN EPIPHANY: 1992 
What had happened after organ transplantation was recog-
nized in 1992 when donor leukocyte chimerism was de-
tected in the peripheral tissues or blood of all 30 human 
kidney or liver recipients studied 2-1/2 to 30 years posttrans-
plantation.14-17.25 Sampling was from blood and multiple 
tissue sites. The sparse chimerism. in which dendritic cells 
were prominent. was demonstrated with donor HLA allele-
specific monoclonal antibodies. In addition. the presence of 
Y chromosomes in female recipients of male organs was 
documented with in situ hybridization.2b Finally, donor 
alleles of chromosome 6 (HLA) and/or chromosome 2 (sex) 
were proved with polymerase chain reaction (peR). 
The Two-Way Paradigm 
With this information. we postulated that clinical organ 
transplantation under immunosuppression involved a dou-
ble immune reaction which had host-vs-graft (HVG) as well 
as graft-vs-host (GVH) arms (Fig 5). The characteristic 
cycle of immunologic crisis and resolution that is the basis of 
all successflli organ transplantations was the product of this 
bidirectional modulation. The reciprocal neutralization of 
the two arms explained the blind folding and thus the poor 
prognostIc value of HLA. matching for organ transplanta-
tion.:7 The cancellation effect also explained the rarity of 
GVHD. even with tr:Jnsplantation of lymphoid-rich organs 
like the liver Jnd intesttne. I .. - 17,25.:K Because the cell trai-
ncking is hi directional. both the allograft and recipient 
hecome genetic composltes (Fig 6. upper panel). In essence. 
the passenger leukoCYtes contamed in the organ allografts 
constituted a rapidly disseminated lragment ot extramedul-
larv donor hone marrow I shown :is a bone silhouette in 
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Fig 6. Two-way paradigm with which transplantation is seen as 
a bidirectional and mutually cancelling immune reaction that is 
predominantly HVG with whole organ grafts (upper panel) and 
predominantly GVH with bone marrow grafts (lower panel). 
Figure 6, upper panel) that contains pluripotent stem 
cells.29 
In the mirror image of successful bone marrow transplan-
tation to cytoablated recipients (Fig 6, lower panel), a 
previously unsuspected trace population of host leukocytes 
invariablv can be found. 3o.3t With either organ or bone 
marrow transplantation. veto and suppressor cells, cytokine 
profile changes. and enhancing antibodies were viewed as 
derivative (and accessory) phenomena following the pri-
marY event of mutual cell engagement (Fig 6). 
Thus. the operational principle of organ allograft accep-
tance bv chimerism (Fig i) was the same as in the neonatal 
mode!.:·J cyroablation-dependent hone marrow transpian-
tatlon.:·3 ..1-X and mixed chimerism tolerance models. The 
iast included the parabiosis models of Martinez et al 32 and 
those of Slavin et :11.'" Ildstad and Sachs.]" and Thomas et 
al .. '5 The theme of chimensm had come full circle to the 
clbservatIons bv Rav Owen 51 years ago of natural tolerance 
in freemartm cattle .. ]'> 
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Fig 7. Continuum of chimerism from observations of Ray Owen in freemartin cattle to the discovery in 1992 of microchimerism in 
organ recipients. 
Transplant Success and Failure Redefined 
Successful transplantation meant that chimerism had been 
introduced which might or might flot be dependent on 
immunosuppression for stability. Failure connoted the ther-
apeutically uncontrollable ascendancy of a HVG or GVH 
reaction. The explicit warning contained in this de fin i-
tion l4- 16 was that quantitation of chimerism could not be 
used to guide drug-weaning decisions. This conclusion has 
sometimes gone unheeded. has not been understood. or 
perhaps simply has been used as a strawman for debating 
purposes. 
Level Vs Duration of ChimerIsm 
There is substantial reason to believe that the level of 
chimerism is less important than its duration.ls.lt> which is 
best illustrated by experience with hepatic transplantation. 
In rodent liver transplant models. the cause (chimerism) 
and effect (tolerance) are almost contemporaneous. In most 
mouse24 and several rat strain combinationsKgTKP~ tolerance 
to liver allografts does not even require immunosuppres-
sion. The same observation had been made in the mid-
19605 by Cordier et al.·w Peacock and Terblanche."O and 
Caine et al41 in about 15% of outbred pigs (Fig 8). In 
contrast. chimerism and tolerance are separated bv months 
or years despite immunosuppressIOn in outbred dogs iJ and 
humans. IS . la In some. the drug-free end point may never be 
reached. necessitating a lifetime of immunosuppression to 
maIntaIn hepallc allogr::Jtt stability. One c::Jn only assume 
that the tIme to reach stable chlmensm In an animal-to-
human comoination will be otf the scale shown In Fig ~K 
Adjunct Bone Marrow Infusion 
All transplantation tolerance strategies are direct or indi-
rect attempts to alter the donor/recipient leukocyte inter-
action. The infusion of unaltered donor bone marrow in 
organ recipients,42.43 a strategy long advocated by Monaco 
and others.4.1.44 is the most primitive example. Our clinical 
trials with adjunct bone marrow for organ recipients45.46 
(and further reported in this issue) were based on the 
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Fig 8. Time between cause (chimerism) and effect (donor-
specific tOlerance) atter iiver allotransplantation In different spe-
cies. Note that Immunosuppression IS not universally required In 
three of the five species shown. 
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Fig 9. Explanation of obligatory MHC matching for bone mar-
row transplantation in cytoablated recipients (second and fourth 
teeter totters) vs freedom from this restriction (first and third 
teeter totters) if the host immune system is intact. 
premise that persistent chimerism could be increased with-
out affecting the rate of acute rejection and without increas-
ing the risk of GVHD. providing immunosuppression was 
given to both immunocyte populations equally.15.IM5 These 
expectations have been verified in approximately 200 cases 
involving all of the major organs induding the intestine. 
These were in essence safety questions. The therapeutic 
hypothesis was quite a different matter. Here the premises 
were that the threat of delayed acute and chronic rejection 
would be reduced and that the frequency of ultimate drug 
independence would be increased. Full efficacy evaluation 
is expected to take the same 5.. to 10 years shown in Fig 8, 
the time frame already delineated by three decades of 
human experience with MHC-illcompatible liver and bone 
marrow transplantation. ls. lo 
Procedures that selectivelv alter one of the interacting 
arms are potentiallv hazardous. exemplitied by the histori-
cal bone marrow transplant experience with GVHD after 
unloading the host immune system bv cvtoablation (Fig 9. 
lower panel). Delaved multiple bone marrow infusions. 
currentlv being evaluated in Miami."' could be a more 
subtle example in which the delaved uploading of a partiallv 
tolerant reclpient with infused donor cells could have an 
increased GVHD potential. We will depend on the MiamI 
team tor accurate mformation about the dimenSIOns of the 
risk or delayed bone marrow infUSIOns in human organ 
reCIpients. 
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Fig 10. Experimental models in rodents revealing the risk of 
GVHD with the delayed migratIon of natve passenger leukocytes 
(see text) from subsequently transplanted organ. Liver-bone 
marrow experiments were reported by Demetris et al.23 Similar 
observations with kidney-bone marrow have been made by 
Persico et al. 48 
Warnings have come from rat models in which combined 
bone marrow and liver transplantation done simultaneouslv 
under a short course of tacrolimus was well rolerated. i3 
However, when the transplants were staged. the second 
graft (even if it was the organ) always caused lethal GVHD 
(Fig 10). The naive donor leukocytes delivered to the 
primed rats mimicked the outcome of a parent-to-defense-
less offspring FI hybrid model.23 Persico et al4M have shown 
the GVHD potential with either simultaneous or staged rat 
bone marrow and kidney allografts (Brown Norway -> 
Lewis) without any immunosuppression. 
XENOTRANSPLA.NTATION 
Xenotransplantation inevitably must follow guidelines im-
posed by the two-way paradigm.-l" The necessity for chimer-
ism was recognized a dozen years ago by I1dstad and 
Sachs;'-l based on evidence from the rat ~ mouse combi-
nation. 
The creation of transgenic animals is in essence an 
attempt to improve the cross species tissue match. designed 
to reduce the acute barrier of humoral rejection. This 
principle. with emphasis on the transfection in pigs of 
human complement regulatorv genes. was tirst postuiated 
hv Platt and Bach'o and ventied bv David White and Jeffrey 
Platt of Cambridge and Duke University. respectively (sum-
marized in refs. 5] to 53). 
Such procedures Will not. however. resolve the problem 
<If m:lIntnmmg cohabitation ni the animal and human 
immune systems for the oredictablv long period required 
tor theIr stable merger.":·<' 
j 
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Fig 11. Experiments of Zanjani showing the feasibility of induc-
ing neonatal xenogeneic tolerance. by the Intraperitoneal infu-
sion of human leukocytes into sheep fetuses early In their 
development. 
Zanjani Sheep Experiments 
A potential crack in the xenotransplant wall has been 
suggested by the experiments of Zanjani et al,54.55 using a 
modification of the Billingham-Brent-Medawar mouse 
model. At the 40- to 50-day stage of the 4- to 5-month sheep 
gestational period. sheep embryos were inoculated intra-
peritoneally with leukocytes from human fetal livers, or 
with human stem cells purified from adult bone marrow 
(Fig 11). A handful of the sheep fetuses completed their 
intrauterine life in a healthy state and have a stable 5% or 
higher human leukocyte ch'imerism 6 to 7 years later. The 
chimeric bone marrow has been adoptively transferred by 
inoculation of other sheep fetuses.55 
Xenogeneic Chimerism in Pigs 
Is it necessary to go back so far in gestation for inoculation, 
or to use stem cell-rich preparations? One year ago, one of 
us (A.S.R.) inoculated 12 pigs with 5 x 109 unaltered IV 
human bone marrow cells a few hours after birth, with no 
immunosuppression (n = 2) or with subsequent tacrolimus 
only (n = 5) or in combination with mycophenolate (MMF) 
(n = 5). The best results were without immunosuppression 
(Table 2). During the ensuing year. all of the five surviving 
animals-now weighing 350 to 410 Ib-have had low-level 
blood (Fig 12) and/or bone marrow chimerism. 
In related experiments in which unaltered human bone 
marrow was infused into cvtoreduced adult baboons (7.5 Gv 
total lymphoid irradiation'). human colony-forming units ~f 
Table 2. Recipient Survival After Human-to-Pig Bone 
Marrow Transplantation 
Survival 
Groups Treatment (at 1 y) 
I 2 Human Done marrow 2/2 
II Human bone marrow - FK 506 2/5 
III 5 Human bone marrow.,. FK 506 • MMF 1/5 
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Fig 12. Ethidium biomide-stained gel of electrophoresed prod-
ucts of double hot start peR amplification of peripheral blood 
mononuclear cells (PBMC) obtained from human -+ pig bone 
marrow recipients at 340 days postinfusion. A primer for DR4 
was used for detection of human cells; PBMC from untreated 
animals and DR4 + individuals were used as negative and 
positive controls, respectively. Note human DNA is present in 
all except pig 1 (bone marrow + FK 506 + MMF) blood 
samples. 
all lineages have been grown (18 months posttransplanta-
tion) from the baboon bone marrowK~S Our assumption is 
that imerspecies cellular tolerance. if it develops at all 
(particularly in the human -- neonatal pig model), will 
require protracted mutual exposure of the two cell popula-
tions. When the five pigs with human chimerism were tested 
at 11 months. there was evidence of donor-specific hypore-
activity in three of the five animals (Fig 13). This had 
become more pronounced with time (Fig 14). 
However. the critical question is whether humoral immu-
nity will be abrogated as has been reponed by AksentiJevich 
et al57 after rat -- mouse xenotransplantation. In the serum 
of Zanjani's humanized sheep.'x antihuman endothelial 
antibodies were detectable with in vitro assavs. even after 2 
years of stable chimerism. . 
The decisive test of sheep - human transplantation 
could not be remotely considered without preliminary 
parallel study of baboonized sheep. This experIment is 
underwav in our laboratory after producing baboon chimer-
Ism In pigs rather than 10 sheep. The uitlmate prechmcaJ 
test will be plg-to-baboon organ transplantation. 
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Fig 13. Mixed lymphocyte reactivity in live human -- pig bone 
marrow transplant recipients at approximately 1 year postinfu-
sion. Pig PBMC were used as responders against either donor or 
third-party splenocytes in a 6-day proliferative assay; the wells 
were pulsed with eH) thymidine (1 /-LCi/well) and harvested 12 to 
14 hours later for the determination of Its incorporation. The 
results are expressed as stimulation index (experimental CPM/ 
background CPM). 
Adoptive Transfer of Xenogeneic Tolerance 
Such experiments are difficult, expensive, and may take 
years. However. if a level of interspecies compatibility is 
achieved in the inoculated pigs. these "golden animals" 
could become a renewable resource that will permit colony 
expansion by transferring the preadapted bone marrow to 
supralethally irradiated adult pigs or to newborn piglets. 
The eventual clinical objective would be to transfer the 
humanized pig bone marrow to cytoablated patients in 
preparation for a subsequent transplantation of a chimeric 
organ obtained from the expanded colony (Fig 15). 
Transgenic and Chimerism Technologies Combined 
Aside from the observations by Rice et al,58 there has been 
other evidence that chimerism alone will not ameliorate the 
hyperacute rejection that follows xenotransplantation be-
Fig 14. Donor-specific mixed 
:ymphocyte reactivity In a hu-
':lan ..... pig recipient of unmod-
ified bone marrow at 349 days 
as compared to that of 75 days 
postinfuslon. For methods. refer 
to the legend of Fig 13. =. do-
nor: •. third party. 
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Fig 15. Possible strategy in which humanized (chimeric) pigs 
are inoculated at birth with unaltered human bone marrow. The 
hypothesis is that the lengthy mutual exposure of the two 
leukocyte populations will lead to tolerance which can be 
transferred to cytoablated or untreated newborn pigs. or ulti-
mately to cytoablated prospective human organ recipients (see 
text). If this procedure is performed on pigs With human com-
plement regulatory genes. the chance of a practical solution to 
pig ...... human xenotransplantation should be improved. 
tween discordant species (summarized in ref. 49). Species 
restriction of complement activation has been described in 
earlier reports of Valdivia et a1 59,60 and has been strongly 
reinforced by the recent observations of Rajasinghe et al bl 
in a rat -> sheep variation of the original Zanjani model. In 
the latter experiments. sheep fetuses hyper acutely rejected 
rat cardiac xenografts in the absence of antirat antibodies 
(alternative pathway). 
Because the liver is the primary source of complement 
svnthesis.62•63 it will not be surprising if the presence of 
l~ukocyte chimerism fails to reduce the complement acti-
vation that has been known for more than 30 years to be 
highly targeted to the vasculature of whole organ allo-
grafts04- 66 and xenografts.67•b8 By inducing chimerism in 
pigs that have human complement regulatory proteins in 
75d P~9d 
POST D!'>! INFUSION 
26 
their organs at birth. the problems of complement activa-
tion and cellular tolerance can be jointly attacked with the 
strategy shown in Fig 15. 
SUMMARY AND CONCLUSIONS 
The assumption for the last third of a century that stem 
cell-dflven hematolymphopoictic chimerism was irrelevant 
to successful conventional whole organ transplantation has 
prompted alternative inadequate explanations of organ 
allograft acceptance. This assumption clouded the hiologic 
meaning of successful organ as well as bone marrow 
transplantation, and precluded the development of a cardi-
nal principle that accommodated all facets of transplanta-
tion. 
Recognition of this error and the incorporation of the 
chimerism factor into a two-way paradigm have allowed 
previous enigmas of organ as well as bone marrow engraft-
ment to be explained. No credible evidence has emerged to 
interdict this interactive concept. If the two-way paradigm is 
correct, it will allow the remarkable advances that have 
been made in basic immunology to be more meaningfully 
exploited for transplantation. including that of xenografts. 
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